Becari C, Teixeira FR, Oliveira EB, Salgado MC. Angiotensinconverting enzyme inhibition augments the expression of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 301: H565-H570, 2011. First published May 20, 2011 doi:10.1152/ajpheart.00534.2010.-Mounting evidence suggest that tissue levels of angiotensin (ANG) II are maintained in animals submitted to chronic angiotensin-converting enzyme (ACE) inhibitor treatment. We examined the expression levels of transcripts for elastase-2, a chymostatin-sensitive serine protease identified as the alternative pathway for ANG II generation from ANG I in the rat vascular tissue and the relative role of ACE-dependent and -independent pathways in generating ANG II in the rat isolated carotid artery rings of spontaneously hypertensive rats (SHR) and Wistar normotensive rats (WNR) treated with enalapril for 7 days. Enalapril treatment decreased blood pressure of SHR only and resulted in significantly more elastase-2 mRNA expression in carotid artery of both enalapril-treated WNR and SHR. Captopril induced a comparable rightward shift of concentration-response curves to ANG I in vehicle and enalapril-treated rats, although this effect was of lesser magnitude in SHR group. Chymostatin induced a rightward shift of the dose response to ANG I in vehicle-treated and a decrease in maximal effect of 22% in enalapril-treated WNR group. Maximal response induced by ANG I was remarkably reduced by chymostatin in enalapril-treated SHR carotid artery (by 80%) compared with controls (by 23%). Our data show that chronic ACE inhibition was associated with augmented functional role of non-ACE pathway in generating ANG II and increased elastase-2 gene expression, suggesting that this protease may contribute as an alternative pathway for ANG II generation when ACE is inhibited in the rat vascular tissue. serine protease; chymostatin; enalapril THE EXISTENCE OF LOCALLY FORMED renin-angiotensin system components in multiple tissues has led to the assumption that angiotensin (ANG) II may act as a local hormone; it may either potentiate systemic functions or have entirely separate activities that meet tissue needs (1, 6, 24). Although angiotensinconverting enzyme (ACE) is considered essential to ANG II formation, particularly in the vascular space, the existence of alternative pathways to ACE for ANG II generation in tissues of different species has been reported (5, 12, 19, 21, 23, 35, 39) . Among the non-ACE ANG II-forming enzymes, a functional role in the cardiovascular system has been attributed for the chymostatin-sensitive serine proteases, as the human chymase (36) and rat elastase-2 (ELA2; Refs. 25, 32). ANG II formation has been ascribed for chymase in human arteries (28, 31) or ELA2 in rat arteries (2, 34). A remarkable feature of rat ELA2 as an ANG I-converting protease is that it does not destroy the product ANG II (25, 33), a property that is shared with some chymases such as human (35), baboon (11), and dog (4) but not rodent chymases, which split ANG I at its two potential chymotryptic cleavage sites, Tyr (16, 18, 38). To further strengthen a possible importance for ELA2 for ANG I processing in vivo is the fact that the catalytic efficiency of ELA2 for ANG I is significantly higher than ACE (25, 30). Although ACE inhibitors are of established benefit for treatment of hypertension and heart failure, plasma ANG II concentrations do not decrease, despite continued inhibition of ACE in patients that received chronic treatment with effectively doses of ACE inhibitor (3, 13), suggesting that non-ACE synthetic pathways for ANG II generation are activated and providing important evidence that non-ACE mechanisms play an important role maintaining normal steady-state ANG II levels in tissue during chronic ACE inhibition. Thus we tested the hypothesis that ELA2, an ANG II-generating enzyme present in the rat tissues, is activated when ACE is inhibited. In the present study, we examined the expression levels of transcripts for ELA2 and its contribution for ANG I conversion to ANG II in carotid rings of normotensive and spontaneously hypertensive (SHR) rats chronically treated with the ACE inhibitor enalapril.
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MATERIALS AND METHODS

Animals.
The experiments were conducted employing 9-to 12-wkold male SHR and Wistar normotensive rats (WNR) that were maintained in a controlled environment with a constant 12:12-h light-dark cycle and provided food and water ad libitum. The rats received enalapril (10 mg·kg Ϫ1 ·day Ϫ1 ; Galena; Campinas, São Paulo, Brazil) or vehicle (water) by oral gavage for 7 days. At the end of the treatment period (3 h after the last administration of enalapril), two sets of experiments were performed in separate animals. The first included collection of blood and tissues for determination of ACE activity or ACE, ANG II receptors (AT 1R and AT2R), and ELA2 mRNA expression. In the second set of experiments, carotid artery was collected for in vitro experiments. All surgical procedures were performed on rats anesthetized with tribromoethanol (250 mg/kg ip), and experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were reviewed and approved by the Animal Care and Use Committee of the Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo.
Blood pressure measurements. Systolic pressure was measured in unanesthetized rats using the tail-cuff plethysmography method, before and on the sixth day of vehicle or enalapril treatment (n ϭ 13), and final systolic pressure value was obtained by averaging three successful readings.
ACE activity. ACE activity in plasma and carotid homogenates (n ϭ 4) were determined as previously described (19), using Hip-His-Leu as substrate, and expressed in nanomoles of His-Leu per minute per milliliter of plasma or gram of tissue.
Isolated carotid rings. The carotid rings were suspended in an organ bath set up for isometric tension measurements, as previously described (2) . Only one peptide was tested in each ring, and concentration-response curves to ANG II or ANG I were obtained in control conditions and after a 50-min period in the presence of the a protease inhibitor or ANG II receptor antagonist in the same preparation (2). The ACE inhibitor captopril (10 mol/l), the serine protease inhibitor chymostatin (100 mol/l), or the AT 1R antagonist losartan (1 mol/l) was added 30 min before the second curve. All peptides and inhibitors were purchased from Sigma Chemical (St. Louis, MO).
Real-time PCR. Total RNA from rat tissues was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) and treated with DNase (Amersham Pharmacia, Piscataway, NJ). Reactions were performed using Platinum SYBR Green qPCR SuperMix-UDG with ROX (Invitrogen). Briefly, reaction conditions were as follows: initial (50°C, 2 min; 95°C, 10 min), followed by 40 cycles of denaturation (95°C, 15 s), and annealing/extension (60°C, 1 min) using an Applied Biosystems 7500 Fast Real-time PCR System. Specific primers were designed based on GenBank sequences and were used to amplify fragments from ELA2 (forward: 5=-GCCTCTCCACCTCGGAAT-3= and reverse: 5=-GTGCGTTCCCAAGGTGAC-3=), ACE (forward: 5=-GCTCAACGGCTACTCTGATG-3= and reverse: 5=-CCTAGCAG-GTGAGCAGGAATG-3=), AT 1R (forward: 5=-AACAACTGCCT-GAACCCTCT-3= and reverse: 5=-TCAGAACAAGACGCAGGCT-3=) and AT2R (forward: 5= TCTGTCTCAAAG AAGGAATCCC C-3= and reverse: 5=-CCAACACAACAGCAGCTGC-3=), and ␤-actin (forward: 5=-AGAAGATGACCCAGATCATGTTT-3= and reverse: 5=-AGCAGCCGTGGCCATCTCTTGCTC-3=). Amplification of ␤-actin was used as the internal control, and the results were expressed as the relative gene expression using the comparative Ct method (20) . Additionally, ethidium bromide-stained agarose gel electrophoresis was performed in all PCR products generated to confirm the size of the products (ELA2, 250 bp; ␤-actin, 210 bp).
Immunohistochemistry for ELA2. Rat ELA2 was purified as described by Paula et al. (25) and used to immunize rabbits. Preceding the first immunization, a blood sample was drawn to obtain preimmune serum. Immunization of animals was performed by three intradermal inoculations of ϳ250 g of purified ELA2 at a 21-day interval. The enzyme was diluted in Freund's complete adjuvant for the first inoculation, in incomplete Freund's adjuvant for the second inoculation, and in saline for the third inoculation. After a 15-day period of the last inoculation, a partial bleeding was performed to obtain the serum and the IgG-enriched fractions were obtained from rabbit antiserum after being submitted to ammonium sulfate precipitation. This antibody was unsuccessful in Western blot application in detecting endogenous protein but was suitable for immunolocalization. Cross sections (5 m) of frozen rat carotid arteries, after been incubated in 1% BSA in PBS for 1 h, were incubated overnight with primary antibody anti-ELA2 (1:1,000) at 4°C and then rinsed and incubated with peroxidase-conjugated secondary antibody (rabbit anti-IgG) at 25°C for 1 h, followed by 3,3=-diaminobenzidine (Sigma) staining. Sections were then counterstained with Mayer's hematoxylin and examined by light microscopy. The control experiments consisted of replacing the primary antibody with equal dilution of preimmune rabbit serum. For control staining, ELA2 antibodies were preabsorbed with the purified enzyme used to immunize the rabbits.
Statistical analysis. Responses to ANG II and ANG I were measured as increases in tension (mg), and concentration-response curves from individual experiments were grouped to generate mean curves to angiotensin peptides. Curves obtained in the absence and presence of the given inhibitor were analyzed using nonlinear regression (GraphPad Prism Software), and log half-maximal effective concentration (pD2) values and maximum contractile responses were obtained. At least two preparations were obtained from each rat, and one vessel from each rat received a particular treatment (n ϭ number of artery rings). Comparisons were performed with Student's paired or unpaired t-test and, where more than two groups were being compared, one-way ANOVA with a posttest of Newman-Keuls. Values were expressed as means Ϯ SE. The statistical analysis was performed using the GraphPad Software, and statistical significance was accepted when P Ͻ 0.05.
RESULTS
Effect of enalapril treatment on systolic blood pressure and ACE activity. Blood pressure measured on the sixth day of enalapril treatment was markedly decreased in SHR (from 178 Ϯ 5 to 135 Ϯ 2 mmHg; P Ͻ 0.0001; n ϭ 13) but unchanged in WNR (Fig. 1, A and B) . In the groups that received only vehicle, blood pressure did not change. While plasma ACE activities of SHR and WNR were similar, ACE activity measured in carotid tissue of SHR was significantly decreased compared with that of WNR and enalapril treatment completely inhibited ACE activity in both plasma and carotid arteries (Fig. 1, C and D) .
Estimation of the contribution of ACE activity to ANG I conversion to ANG II. Since enalapril displays a rapid rate of dissociation during tissue manipulation leading to an underestimation of functional ACE inhibition (14) , an ACE inhibitor was added to the solution perfusion. In carotid rings from WNR, addition of captopril, in vitro, induced a similar rightward shift of the concentration-response curve to ANG I in both vehicle-treated (pD 2 ϭ from 8.98 Ϯ 0.11 to 6.99 Ϯ 0.07; P ϭ 0.0003) and enalapril-treated (pD 2 ϭ from 8.44 Ϯ 0.05 to 6.59 Ϯ 0.08; P Ͻ 0.0001) groups (n ϭ 4) but did not affect the contractile responses induced by ANG II (Fig. 2) . In preparations from SHR, captopril also induced a similar rightward shift of the concentration-response curve to ANG I in vehicletreated (pD 2 ϭ from 8.33 Ϯ 0.06 to 7.09 Ϯ 0.11; P Ͻ 0.0001) and enalapril-treated (pD 2 ϭ from 8.23 Ϯ 0.26 to 6.61 Ϯ 0.16; P ϭ 0.0007) groups (n ϭ 5) but did not affect the contractile Fig. 1 . Effect of vehicle or enalapril treatment on systolic blood pressure of spontaneously hypertensive rats (SHR; A; n ϭ 13) and Wistar normotensive rats (WNR; B; n ϭ 7) and on angiotensin-converting enzyme (ACE; n ϭ 4) activity in plasma (C) and carotid artery (D). Data are reported as means Ϯ SE. *P Ͻ 0.0001, compared with period before treatment. **P Ͻ 0.0001, compared with WNR. responses induced by ANG II (Fig. 3) . These data (Figs. 2 and  3 ) also indicate that contribution of ACE to ANG I to II conversion was of less importance in SHR than in WNR carotid tissues, since the magnitude of the displacement of the curves in the presence of captopril was smaller in SHR group. The contractile effects of ANG I and II were abolished in the presence of the AT 1 R antagonist losartan (data not shown).
Estimation of the contribution of a chymostatin-sensitive serine protease activity to ANG I conversion to ANG II. In carotid rings of WNR treated with vehicle, chymostatin induced a significant (P ϭ 0.0007) shift of the concentration-response curve to ANG I to the right (pD 2 ϭ from 8.70 Ϯ 0.07 to 8.10 Ϯ 0.06; n ϭ 8) without affecting the maximal effect. In vessel from WNR treated with enalapril, however, the maximal contractile response elicited by ANG I was significantly (P ϭ 0.008) reduced by 22% (Fig. 4B) . Attenuation of the maximal response achieved by ANG I in carotid rings from SHR given either the vehicle or enalapril was also observed (Fig. 5B ). This decrease in maximal response was much more prominent in carotid of enalapriltreated (by 80%; P Ͻ 0.0001) than in vehicle-treated SHR (23%; P ϭ 0.0008). Chymostatin did not affect the response to ANG II in either vehicle-or enalapril-treated WNR and SHR carotid arteries (Figs. 4A and 5A) .
Effect of enalapril treatment on ELA2 mRNA expression. Figure 6 documents that the treatment with enalapril augmented the expression of ELA2 mRNA in carotid artery as well as in heart tissue of both WNR and SHR. In addition, these data also show that SHRs presented an increased expression of this enzyme in both tissues compared with the normotensive control group. Enalapril treatment had no significant effect on the expression of ACE or AT 1 R and AT 2 R mRNAs in carotid arteries of SHRs compared with vehicle-treated group (data not shown).
Immunohistochemistry localization of ELA2 in WNR and SHR carotid arteries. Staining for ELA2 was clearly detected in the carotid artery endothelial layer of the intima and media layer cells, most probably the smooth muscle cells, of both WNR and SHR, although staining intensity was much stronger in SHR arteries, as shown in the representative example of three immunostaining experiments (Fig. 7, A and B) . No immunolabeling was found in control sections incubated with preimmune sera instead of the primary antibodies (data not shown). The specificity of the antibody used in these tissues was confirmed with preadsorption of the primary antibody anti-ELA2, where the typical lack of staining in the intima and media layers of WNR and SHR carotid sections is illustrated in Fig. 7, C and D, respectively. 
DISCUSSION
We examined the effect of 7-day treatment with an ACE inhibitor on the contribution of an ACE-dependent and -independent ANG II-forming activities in carotid artery of SHRs and normotensive rats. Chronic ACE inhibition with enalapril was associated with a marked increase of a chymostatininhibitable ANG II formation in both WNR and SHR carotid arteries. Moreover, the augmented role of the non-ACE activity in converting ANG I to ANG II in the carotid artery of rats receiving enalapril, as assessed by the effect of the serine protease inhibitor chymostatin on the ANG I-induced vasoconstrictor responses, was accompanied by a significant increase in carotid artery ELA2 gene transcription, an efficient ANG II-forming serine protease that has a functional role for ANG II generation in the rat vasculature (2, 34) .
The effect of enalapril treatment on the carotid artery ELA2 mRNA seems to be rather specific because ACE and ANG II receptor gene transcriptions were not changed in this artery; however, in this treatment condition, upregulation of ELA2 gene was also found in heart tissue, an important target for using ACE inhibitor therapy. These data suggest that alternative pathway to ACE has an important role in preserving tissue levels of ANG II when ACE activity decreases. In support for this assumption are the findings that cardiac tissue ANG II concentration was unaffected by chronic treatment with ACE inhibitor in Lewis rats (8) or hamsters (37) , although plasma ANG II decreased. The fact that ACE inhibitor treatment had no significant effect on the expression of ACE mRNA correlated with the similar rightward shift of the concentrationresponse curves to ANG I induced by captopril in carotid arteries of enalapril-treated and untreated rats. Also, the fact that the ANG II-induced constrictor responses were unaffected by enalapril treatment is in agreement with the finding that ANG II receptors gene expression were not modified by enalapril treatment and suggests that ANG II tissue levels did not change, since it is well established that a decrease in ANG II concentration in vivo induces upregulation of ANG II receptors (10). Although we cannot provide any data on the mechanisms involved in the enalaprilinduced upregulation of ELA2 mRNA expression, we can exclude the blood pressure lowering effect of ACE inhibition, since this effect was observed only in SHRs and the increase in ELA2 mRNA was detected in both enalapriltreated SHR and WNR tissues.
Accumulating evidence indicates that the effects induced by ACE inhibitors go beyond blocking the ACE dipeptidyl carboxypeptidase activity responsible for the release of ANG II from ANG I or inactivating bradykinin. Some of the effects of ACE inhibitors on cardiovascular function can be attributed to the activation of an ACE signaling cascade that leads to an increase in the expression of genes such as cyclooxygenase-2 resulting in an increase in the production of prostacyclin (15) . Interestingly, Lewis rats chronically treated with an ACE inhibitor exhibited an increase in cardiac ACE2 gene expression (8) . Unlike ACE, ACE2 does not process ANG I to ANG II but functions as a carboxypeptidase responsible for the metabolism of ANG II to the heptapeptide angiotensin 1-7 (ANG 1-7) that exhibits vasodilator, antifibrotic, and antiproliferative actions (7, 9) . Thus maintenance of tissue ANG II levels by non-ACE pathway when ACE is inhibited, combined with increases of carboxypeptidase activities capable of processing ANG II within the tissue, as ACE2 or carboxypeptidase A-like enzymes (26) , would favor an enhanced accumulation of ANG 1-7 that may counteract the detrimental effects associated with increases in ANG II levels. However, this hypothesis could not be confirmed in the condition of our study, since ACE2 mRNA expression in carotid and heart tissues of Wistar rats was not modified by enalapril treatment (data not shown). Conversely, the alternative pathway for ANG II generation, as ELA2, when ACE is inhibited may confer benefits since dual ACE/AT 1 R blockade may increase the risks of adverse effects, including hyperkalemia, hypotension, and worsening renal failure (16, 28) .
Our data also show that vehicle-treated SHRs had a decreased tissue ACE activity compared with the vehicletreated normotensive rats, as described by others (22, 29) , associated with an increased expression of ELA2 mRNA and protein in carotid arteries. These findings are in agreement with the functional experiments since the displacement of the ANG I concentration curve induced by captopril was less important in carotid arteries of SHRs than in those of WNR while the effect of chymostatin was more prominent in arteries of SHR. In addition, the finding that ELA2 protein was detected in the arterial wall, including the intima layer, provides strong evidence supporting a functional role for ELA2 in the generation of ANG II in the rat vasculature. In fact, a previous report (34) from our laboratory has demonstrated that cultured mesenteric artery endothelial cells are capable of producing ELA2.
In summary, chronic administration of enalapril changes the balance of non-ACE and ACE-dependent ANG II forming activity in the rat carotid artery increasing the non-ACE pathway functional role. Furthermore, enalapril treatment induced an increase in mRNA expression of ELA2, a highly efficient ANG II-forming serine protease in rat vasculature.
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